


Farudodstat

Cat. No.:	HY-129239												
CAS No.:	1035688-66-4												
Molecular Formula:	C ₁₉ H ₁₄ F ₂ N ₂ O ₃												
Molecular Weight:	356.32												
Target:	Dihydroorotate Dehydrogenase; DNA/RNA Synthesis; Apoptosis												
Pathway:	Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Apoptosis												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (350.81 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.8065 mL	14.0323 mL	28.0647 mL
		5 mM	0.5613 mL	2.8065 mL	5.6129 mL
10 mM		0.2806 mL	1.4032 mL	2.8065 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (6.09 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.17 mg/mL (6.09 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC ₅₀ of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice ^{[1][2]} .
IC₅₀ & Target	IC ₅₀ : 35 nM (human DHODH enzyme) ^[1]
In Vitro	<p>Farudodstat (0.01-100 μM; for 48 hours) inhibits leukemic cell proliferation. The cell viability is maintained at ~50% at Farudodstat 1 μM and higher^[1].</p> <p>Farudodstat (0.5, 1 μM; for 48 hours) significantly increases cleaved caspase 8^[1].</p> <p>Farudodstat (2, 4 μM; for 96 hours) decreases viability and induces differentiation in primary acute myeloid leukemia blasts</p>

and myelodysplastic syndrome samples^[1].

Farudodstat (1, 2 μ M; pretreatment 1 h before OPP for 1 h) inhibits protein synthesis, as demonstrated by the reduced incorporation of O-propargyl-puromycin (OPP) at protein translation sites in both MOLM-14 and KG-1 cells. Farudodstat causes the downregulation of EIF4B, and RPL6 proteins^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	THP-1, MOLM-14 and KG-1 cells
Concentration:	0.01, 0.1, 1, 10, 100 μ M
Incubation Time:	For 48 hours
Result:	Inhibited leukemic cell proliferation of THP-1, MOLM-14 and KG-1 with IC ₅₀ values of 152 nM, 582 nM, and 382 nM, respectively.

Western Blot Analysis^[1]

Cell Line:	KG-1 and MOLM-14 cells
Concentration:	0.5, 1 μ M
Incubation Time:	For 48 hours
Result:	Significantly increased cleaved caspase 8, increased leakage of cytochrome c from mitochondria into the cytosol and induced cleaved caspase-3 and -7.

In Vivo

Farudodstat (50 mg/kg; oral gavage; once daily; from the day 3 to 30) substantially reduces the number of disseminated tumors and prolongs survival^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NOD.Cg-Prkdc ^{scid} Il2rg ^{tm1Wjl} /SzJ, NGS mice (4-6 weeks old) with MOLM-14 cells ^[1]
Dosage:	50 mg/kg
Administration:	Oral gavage; once daily; from the day 3 to 30
Result:	Substantially reduced the number of disseminated tumors and the size of these tumors. Survival was significantly prolonged.

CUSTOMER VALIDATION

- Biochem Pharmacol. 2022 Aug 27;204:115232.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure an

[2]. Jianbiao Zhou, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA